ULTRA 1, 2, 3 Demonstrate Safety and Efficacy of Adalimumab in Ulcerative Colitis

ULTRA 1, 2, 3 Demonstrate Safety and Efficacy of Adalimumab in Ulcerative Colitis
AdalimumabThree clinical trials -- one an open-label extension study, evaluating adalimumab (Humira) in patients with moderately to severely active ulcerative colitis -- were recently reviewed in an article from collaborators at Icahn School of Medicine at Mt Sinai, AbbVie, and other gastroenterology-focused institutions. Ulcerative Colitis Long-Term Remission and Maintenance with Adalimumab (ULTRA) 1, 2, and open-extension 3 bolstered evidence that adalimumab is beneficial in patients affected with ulcerative colitis, as described by "Four-Year Maintenance Treatment with Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3," published in The American Journal of Gastroenterology. More than 1,000 individuals with moderately to severely active ulcerative colitis were enrolled in ULTRA 1 or 2, and 600 patients were randomized to receive adalimumab in varying doses across a set of treatment groups. Double-blind treatment was sustain
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *